Prognostic impact of peripheral blood
Myelodysplastic Syndromes
WT1
Wilms’ tumour 1
azacytidine
hypomethylating agent
Journal
Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
09
2020
revised:
22
11
2020
accepted:
06
12
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
24
12
2020
Statut:
epublish
Résumé
To determine the impact of peripheral blood (PB)
Identifiants
pubmed: 33354513
doi: 10.1016/j.lrr.2020.100231
pii: S2213-0489(20)30037-6
pmc: PMC7744716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100231Informations de copyright
© 2020 The Author(s). Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tomoya Maeda has received honoraria from Nippon Shinyaku and advisory boards for Janssen. Akira Matsuda has received honoraria from GlaxoSmithKline, Kyowa Kirin, Nippon Shinyaku, Celgene, Alexion, Sanofi, Beckman Coulter, Siemens Healthineers and Shire Japan. Maho Ishikawa has received honoraria from Bristol-Myers Squibb and Pfizer. Kunihiro Tsukasaki has a consultancy in Daiich-Sankyo, Ono Pharma, and HUYA, has received research funding from Bayer and Celgene, and honoraria from Chugai Pharma, Celgene, Mundy and Kyowa Kirin. Norio Asou has received scholarships from Chugai Pharma, Astellas, Sumitomo Dainippon and Eisai and research funding from Novartis and Otsuka Pharma, has consulted for SRL, Nippon Shinyaku, and Novartis and has received honoraria from Kyowa Kirin, Sumitomo Dainippon, Asahi Kasei and Fuji Pharma. Masami Bessho has received honoraria from Chugai Pharma and GlaxoSmithKline. These sponsors had no control over the interpretation, writing or publication of this study. The other authors have no declaration of conflicts of interest to declare in relation to this manuscript.
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Ann Hematol. 2019 Jun;98(6):1383-1392
pubmed: 30877373
Leukemia. 2011 Jul;25(7):1147-52
pubmed: 21494260
J Clin Oncol. 2013 Oct 1;31(28):3557-64
pubmed: 24002510
Mol Cell. 2010 Jan 29;37(2):153-5
pubmed: 20122396
Eur J Haematol. 2019 Sep;103(3):208-214
pubmed: 31211880
N Engl J Med. 2009 Nov 5;361(19):1872-85
pubmed: 19890130
Leuk Res Rep. 2014 Apr 16;3(1):24-7
pubmed: 24809010
Leukemia. 2014 Jan;28(1):78-87
pubmed: 24045501
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Blood. 2000 Dec 1;96(12):3671-4
pubmed: 11090046
Leuk Lymphoma. 2013 Jul;54(7):1450-8
pubmed: 23110324
Ann Hematol. 2010 Jul;89(7):681-9
pubmed: 20237926
Br J Haematol. 2014 Oct;167(1):62-8
pubmed: 24995683
Blood. 2011 Jan 13;117(2):403-11
pubmed: 20940414
Br J Haematol. 2019 Feb;184(3):447-450
pubmed: 29359800
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
J Clin Oncol. 2007 Aug 10;25(23):3503-10
pubmed: 17687155
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Blood. 2016 Aug 18;128(7):902-10
pubmed: 27335276
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Int J Hematol. 2016 Jan;103(1):53-62
pubmed: 26520650